It's Time to Move Forward

Intelligene Diagnostics
10900 S. Clay Blair Blvd, Suite 1400
Olathe, KS 66061
913-258-2302
info@intelligenedx.com
www.intelligenedx.com

Genoptix
2110 Rutherford Rd.
Carlsbad, CA 92008
800-755-1605
clientservices@genoptix.com
www.genoptix.com

CORE Diagnostics
2458 Embarcadero Way
Palo Alto, CA 94303
650-532-9500
info@corediagnostics.net
www.corediagnostics.net

LabCorp
800-444-9111
www.LabCorp.com

Quest Diagnostics
800-222-0446
www.QuestDiagnostics.com

ARUP Laboratories
800-522-2787
www.ARUPLab.com/prosigna

University of Arizona Genetics Core – Clinical services division
1657 E Helen St
Tucson, AZ 85721
520-621-9791
uagcclinical.arl.arizona.edu

University of Kansas Medical Center
Clinical Molecular Oncology Laboratory
Andrew K Godwin PhD
3901 Rainbow Boulevard, Mail Stop 3040
Kansas City, KS 66160
USA
913-945-6391
cmol@kumc.edu
http://www.kumc.edu/school-of-medicine/pathology/clinical-molecular-oncology-laboratory.html

Thomas Jefferson University Hospital
1025 Walnut Street
College Building 401
Molecular & Genomic Pathology Lab
Philadelphia, PA 19107
215-995-4420
zi-xuan.wang@jefferson.edu

City of Hope Clinical Molecular Diagnostic Laboratory
1500 E. Duarte Rd
North West Building
Room 2236
Duarte, CA 91010
888-826-4362
mdl@coh.org

University of Alabama at Birmingham Comprehensive Cancer Center
www3.ccc.uab.edu

University of North Carolina Lineberger Comprehensive Cancer Center
www.unclineberger.org

Baylor Scott & White Health
2401 S 31st
Temple, TX 7650
8254-724-2111
https://www.baylorscottandwhite.com/

Avera Cancer Institute
1000 E 23rd St, Ste 200
Sioux Falls, SD 57105
605-322-3000
http://www.avera.org/services/cancer-care

Providence Health & Services, Oregon Regional Laboratories
4400 N. E. Halsey, Building #3
Portland, OR 97213
866-674-7990
prosigna@providence.org
http://oregon.providence.org/our-services/p/providence-laboratory-services/

Magee-Womens Hospital of UPMC
300 Halket St.
Pittsburgh, PA 15213
412-641-4651
dabbdj@mail.magee.edu

Prosigna is helping oncologies around the world gain more information about their patients' risk of recurrence.

For additional assistance, contact info@prosigna.com

Prosigna is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.